Articles tagged "Heart"

2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
A Molecular Analysis of Graft Survival in the INTERHEART Study
P. Halloran¹, J. Reeve and the INTERHEART investigators²
¹University of Alberta, Edmonton AB, AB, Canada, ²ATAGC, University of Alberta, Edmonton AB, AB, Canada
*Purpose: Rejection is a major cause of graft loss in heart and kidney transplants. The principal diagnosis associated with risk in kidneys is antibody-mediated rejection…
2019 American Transplant Congress
Anemia and Hemolysis on Dapsone Despite Normal Glucose-6-Phosphate Dehydrogenase Activity in Heart Transplant Recipients
K. Lor, E. Kransdorf, J. Patel, M. Kittleson, D. Chang, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Dapsone has been considered an acceptable alternative for pneumocystis jirovecii pneumonia (PCP) prophylaxis in sulfa-allergic or -intolerant transplant patients with normal glucose-6-phosphate dehydrogenase (G6PD)…
2019 American Transplant Congress
TMA Development in Kidney and Heart Xenografts Treated with Anti-CD40 or Anti-CD154 Antibodies
D. H. Ma¹, H. Sasaki¹, J. M. O¹, K. Ahrens¹, D. Becerra¹, C. G. Rickert¹, D. M. Detelich¹, T. Oura¹, W. Somer¹, I. Rosales², R. N. Pierson¹, J. Markmann¹, J. C. Madsen¹, T. Kawai¹
¹Surgery, MGH, Boston, MA, ²Pathology, MGH, Boston, MA
*Purpose: Genetically modified Galactose-α 1,3-galactose knockout transgenic swine expressing human CD55 (GTKO.hCD55) are resistant to hyperacute rejection of xenografts. We compare anti-CD154 and anti-CD40 antibody-based…
2019 American Transplant Congress
Low Frequency Of Canonical Human Leukocyte Antigen Alloimmunization In Heart Transplantation Candidates With Ventricular Assist Devices
G. K. Mahowald¹, S. L. Saidman¹, G. Lewis², V. Pattanayak¹
¹Pathology, Massachusetts General Hospital, Boston, MA, ²Cardiology, Massachusetts General Hospital, Boston, MA
*Purpose: Screening for anti-HLA antibodies in heart transplantation candidates is complicated by transfusions as well as by the presence of ventricular assist devices (VADs), which…
2019 American Transplant Congress
Outcome Of Left Main Stenting After Heart Transplantation
S. Dimbil, J. Patel, B. Azarbal, M. Kittleson, R. Levine, D. H. Chang, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Cardiac allograft vasculopathy (CAV) is one of the major factors limiting long-term survival after HTx. The use of angioplasty and drug-eluting stents is common…
2019 American Transplant Congress
Perioperative Cardiac Xenograft Dysfunction after Orthotopic Transplantation is for Real
M. Mohiuddin¹, A. Singh¹, L. DiChiacchio¹, D. Kaczorowski¹, B. Lewis¹, T. Zhang¹, F. Sentz¹, I. Tatarov¹, D. Parsell¹, P. Odonkor¹, E. Strauss¹, B. Williams¹, K. Deatrick¹, D. Ayares², B. Griffith¹, S. Bartlett¹
¹Department of Surgery, University of Maryland Baltimore, Baltimore, MD, ²Revivicor, Inc, Blacksburg, VA
*Purpose: After successful prolongation of cardiac xenograft survival in a heterotopic position, the next step is to evaluate genetically engineered (GE) pig hearts for their…
2018 American Transplant Congress
Upregulated IL-33 in Heart Transplants Modulates Local Myeloid Populations to Protect against Chronic Allograft Rejection
Z. Zhang,¹ Q. Liu,¹ G. Hussey,² J. Dziki,² L. Mathews,¹ H. Dai,¹ G. Dwyer,^1,3 A. Lucas,¹ M. Oberbarnscheidt,¹ S. Badylak,² H. Turnquist.^1,3
¹University of Pittsburgh, Starzl Transplant Institute, Pittsburgh, PA; ²University of Pittsburgh, McGowan Institute for Regenerative Medicine, Pittsburgh, PA; ³Immunology, University of Pittsburgh, Pittsburgh, PA.
Purpose: Interleukin-33 (IL-33) is an “alarmin”, or a self-derived molecule that triggers pleotropic immune responses after release from damaged tissue. Yet, how IL-33 shapes alloresponses…
2018 American Transplant Congress
IL-21 Regulates Creation of Tertiary Lymphoid Organs in Chronic Allograft Rejection
J. Breidenbach, C. Baum, P. Schroder, S. Stepkowski.
Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Science, Toledo, OH.
Background: IL-21 is a cytokine expressed almost exclusively by cells of the adaptive immune system, making it an attractive target for reducing chronic allograft rejection…
2018 American Transplant Congress
Role of B Cell Intrinsic NLRP3 in the Development of Chronic Rejection
J. Nie,¹ B. Ramaswami,² X. Guo,³ R. Hoffman,² G. Chalasani.³
¹Thoracic Surgery, Huazhong University of Science and Technology, Wuhan, Hubei, China; ²Surgery, Starzl Transplantation Institute, Pittsburgh, PA; ³Medicine, University of Pittsburgh, Pittsburgh, PA.
Endogenous DAMPs elicited during transplantation are recognized via TLR-MyD88 and NLRP3-inflammosome pathways that are expressed in APCs including B cells. Here, we asked whether B…